Published September 21, 2021 | Version v1
Journal article

The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

Additional details

Identifiers

URL
https://hal.science/hal-04237768
URN
urn:oai:HAL:hal-04237768v1

Origin repository

Origin repository
UNICA